Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TNFRSF1A | P19438 | 8/20 | 0.48 |
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | ACLY | P53396 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6091946 | 0.91 | TNFRSF1A (0.48) | NPC1RAB9ASMN1; SMN2TNFRSF1AERN1 | |
| SCHEMBL6093398 | 0.88 | TNFRSF1A (0.50) | NPC1RAB9ASMN1; SMN2TNFRSF1AHDAC6 | |
| SCHEMBL6091620 | 0.81 | TNFRSF1A (0.52) | NPC1RAB9ATNFRSF1ACNR2HDAC6 | |
| SCHEMBL6094833 | 0.78 | TNFRSF1A (0.46) | TNFRSF1ACNR2HDAC6ERN1ACLY | |
| SCHEMBL6091917 | 0.75 | SMN1; SMN2 (0.65) | NPC1RAB9ASMN1; SMN2CNR2HIF1A | |
| SCHEMBL4728444 | 0.72 | TNFRSF1A (0.50) | TNFRSF1AERN1ACLYAVPR1A | |
| SCHEMBL6093796 | 0.71 | TNFRSF1A (0.57) | TNFRSF1ACNR2HDAC6ERN1ACLY | |
| SCHEMBL4727938 | 0.71 | TNFRSF1A (0.54) | TNFRSF1AHDAC6ERN1ACLYAVPR1A | |
| SCHEMBL6040514 | 0.70 | TNFRSF1A (0.53) | NPC1RAB9ATNFRSF1AHDAC6ERN1 | |
| SCHEMBL5571695 | 0.70 | TNFRSF1A (0.69) | TNFRSF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060063828-A1 | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof | ATHEROGENICS, INC. | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063828-A1 | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof | ABCB11, CEL, CYP46A1 | NPC1 95/4885RAB9A 2477/4885SMN1; SMN2 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.